TOTAL: $368.92M | ||||
Company (Symbol)# |
Type Of Financing |
Number Of Shares, Units Or Warrants (M) |
Amount Raised ($M)* |
Investors; Placement Agents; Details (Date)@ |
AltaRex Corp. (Canada; TSE:AXO) |
Warrant exercise |
5.687 shares |
C$5.4 (US$3.66) |
AltaRex received C$5.4M (US$3.66M) from the exercise of special warrants sold 2/29/00 into common shares (4/20) |
Aphton Corp. (APHT) |
Private placement of common stock |
0.49 shares |
$16.22 |
Aphton sold 0.49M shares of common stock at $33 per share to raise $16.22M; Morgan Stanley Dean Witter and Gruntal & Co. assisted in the placement (4/12) |
Aronex Pharmaceuticals Inc. (ARNX) |
Private placement of units |
81 units |
$8.1 |
Aronex sold units for $100,000 each; each unit consists of 36,364 shares of common stock and a five-year warrant to purchase 12,121 shares of common stock at $3 per share; Paramount Capital Inc. acted as financial adviser (4/18) |
Aviron (AVIR) |
Private placement of common stock |
0.14 shares |
$4 |
Under previously filed registration form S-3, Aviron sold 0.14M shares to Acqua Wellington Asset Management LLC at $27.74 per share, raising gross proceeds of $4M; Aviron may sell up to $48M in shares to Acqua over 12 months (4/13) |
BioChem Pharma Inc. (Canada; BCHE) |
Product development investment to be repaid with royalties |
|
C$80 (US$55.18) |
BioChem entered a partnership agreement with the Canadian government through Technology Partnerships Canada, under which the government will invest C$80M (US$55.18M) in BioChem's recombinant protein vaccines program and will be repaid with royalties on commercialized products (4/3) |
Biosyntech Inc. (Canada: OTC BB:BSYI) |
Private placement of units |
1.8 units |
$6.3 |
Biosyntech sold 1.8M units at $3.50 per unit for total proceeds of $6.3M; each unit consists of one share of common stock and one warrant to buy a common share at $4.50 by 3/31/01 (4/20) |
Calypte Biomedical Corp. (CALY) |
Private placement of common stock |
4.1 shares |
$8.4 |
Calypte sold 4.1M shares at $2.05 per share for proceeds of $8.4M; half of the financing was provided by Trilobite Lakes Corp., a wholly owned subsidiary of Claneil Enterprises Inc. (4/13) |
Cytoclonal Pharmaceutics Inc. (CYPH) |
Warrant redemption |
|
$25.7 |
Cytoclonal completed the call for redemption of publicly traded Class D warrants; about 65% of the warrants (2.4M) were exercised, allowing holders to buy one share of common stock at $8.75 for each warrant held (4/17) |
Endorex Corp. (AMEX:DOR) |
Private placement of common stock and warrants |
1.81 shares, warrants for 0.455 shares |
$8.6 |
Endorex raised $8.6M through a private placement of 1.81M shares priced at $4.75 per share to domestic and foreign institutional investors; investors also received warrants to buy 0.455M common shares at $5.91 per share; Paramount Capital Inc. acted as financial adviser (4/13) |
Epoch Pharmaceuticals Inc. (OTC BB: EPPH) |
Warrant redemption |
3.795 shares |
$9.5 |
Epoch raised $9.5M through the exercise of warrants for 3.795M shares of common stock at $2.50 per share (4/10) |
Helix BioPharma Corp. (Canada; TSE:HBP) |
Private placement of units |
3 units |
C$10 (US$6.89) |
Helix placed 3M units at C$3.33 (US$2.29) per unit with a private European investment company, raising C$10M (US$6.89M); the units consist of 3M shares plus warrants to purchase 1.5M shares at C$6.66 (US$4.59) per share for one year and warrants to purchase 1.5M shares at C$10 (US$6.89M) for two years (4/5) |
Hemosol Inc. (Canada; TSE:HML) |
Bought deal financing |
1.06 shares |
C$20.1 (US$13.84) |
Hemosol sold 1.06M shares at $19 each in a bought deal financing with a syndicate of underwriters led by Yorkton Securities Inc. (4/5) |
Integra LifeSciences Corp. (IART) |
Private placement of convertible preferred stock and warrants |
0.054 preferred shares, warrants for 0.3 shares |
$5.4 |
Integra raised $5.4M from investment affiliates of Soros Private Equity Partners LLC, which bought 54,000 shares of Series C convertible preferred stock that are convertible into 0.6M shares of common stock, plus warrants to purchase an additional 0.3M shares at $9 per share (4/6) |
Matritech Inc. (NMPS) |
Warrant exercise |
1.3 shares |
$2.8 |
Matritech raised $2.8M through the exercise of three separate stock purchase warrants in 1Q:00 for 1.3M shares of stock; to date, all but 88,137 warrants have been exercised (4/10) |
NeoRx Corp. (NERX) |
Private placement of common stock |
1.73 shares |
$19 |
NeoRx sold 1.73M shares of common stock at $11 each to institutional investors for gross proceeds of $19M; placement agents were Adams, Harkness & Hill, and Roth Capital Partners Inc. (4/24) |
NeoTherapeutics Inc. (NEOT) |
Private placement of subordinated convertible debentures |
|
$10 |
NeoTherapeutics placed $10M worth of 5% subordinated convertible debentures due 4/6/05; subject to certain conditions, investors agreed to fund two future tranches of up to $10M each and redeemable warrants to purchase up to 4M shares of common stock over a two-year period exercisable at $33.75 per share (for a potential total of $69M); debentures are convertible into common stock at $20.25 per share for the first 90 days, and at the lesser of $20.25 or 101% of the market price thereafter (4/10) |
Neurobiological Technologies Inc. (OTC BB:NTII) |
Private placement of common stock |
1.19 shares |
$6.36 |
Neurobiological Technologies sold 1.19M shares at $5.30 per share for proceeds of $6.36M; investors included Capital Research Co. and Gotham Capital Management; AmeriCal Securities Inc. acted as placement agent (4/19) |
Novopharm Biotech Inc. (Canada; TSE:NVO) |
Private placement of units |
6.85 units |
C$5 (US$3.45) |
Dan Family Holdings Ltd. will purchase 6.85M units at C$0.73 (US$0.50) per unit; each unit consists of one common share and one-half common share purchase warrant; each full warrant may be exercised at C$0.73 per share (US$0.50) during the first year and $1.50 the second year; deal also includes a second tranche in the form of a non-interest bearing facility for C$7M (US$4.83M), from which Novopharm may draw in C$1M (US$0.69M) increments after 8/31/00 (4/3) |
NPS Pharmaceuticals Inc. (NPSP) |
Private placement of common stock |
3.9 shares |
$46.8 |
NPS sold an aggregate of 3.9M shares of common stock at $12 each for gross proceeds of $46.8M ($43.5M net); Prudential Vector Healthcare Group served as placement agent (4/24) |
Oxis International Inc. (OXIS) |
Private placement of units |
ND |
$6.25 |
Oxis raised $1.45M in second tranche of a units placement; units consist of one share of common stock and warrants to purchase two shares of common stock; units in the second tranche were priced at $3.94; one share covered by the warrants may be purchased at $4.92, or 125% of unit price, and the second may be purchased at $5.91, or 150% of the unit price (4/20) |
Procyon BioPharma Inc. (Canada; VSE:PBP) |
Private placement of special warrants |
7.79 warrants |
C$20.4 (US$13.94) |
Procyon offered 7.79M warrants at C$2.62 (US$1.79) each; each warrant will be exercisable, at no additional cost, into one common share and one-half of one common share purchase warrant; each whole warrant entitles holder to purchase a common share for C$3.93 (US$0.68) within two years; Research Capital Corp. led the financing (4/11) |
SangStat Medical Corp. (SANG) |
Line of credit |
|
$30 |
SangStat reached an agreement with Finova Capital Corp. for a $30M credit line at the prime rate of interest plus 0.75% (4/24) |
Sepragen Corp. (OTC BB: SPGNA) |
Private placement of common stock |
3.445 shares |
$2.58 |
Sepragen sold 3.445M shares of common stock at $0.75 per share for gross proceeds of $2.58M; investors include Koyah Leverage Partners LP and Koyah Partners (both managed by ICM Asset Management) and Special Situations Private Equity Fund LP; Crown Point Securities LLC served as placement agent (4/5) |
Siga Technologies Inc. (SIGA) |
Private placement of common stock and warrants |
0.6M shares and warrants |
$3 |
Siga completed a $3M private placement consisting of 0.6M shares of common stock and attached warrants (4/7) |
Synthetic Blood International (OTC BB:SYBD) |
Private placement |
ND |
$2 |
Synthetic Blood received first installment of $5.5M financing commitment from offshore investors (4/3) |
Theratechnologies (Canada; TSE:TH) |
Private placement of warrants |
|
C$10.8 (US$7.35) |
Theratechnologies placed C$10.8M (US$7.35) worth of warrants with an institutional investor entitling the holder to acquire, without additional payment, 1.2M common shares of Theratechnologies' new spin-off Ecopia BioSciences within 18 months of the listing date of Ecopia's shares on a recognized market, or 0.54M shares of Theratechnologies if Ecopia is not listed by 5/5/04 (4/26) |
Trega Biosciences Inc. (TRGA) |
Private placement of common stock |
3.7 shares |
$11 |
Trega sold 3.7M shares of common stock for gross proceeds of $11M (4/5) |
Trinity Biotech (Ireland; TRIBY) |
Private placement of common stock |
4 shares |
$13.4 |
Trinity placed 4M shares at $3.35 per share for gross proceeds of $13.4M; Goodbody Stockbrokers, a subsidiary of AIB Bank in Ireland, served as placement agent (4/5) |
Valentis Inc. (VLTS) |
Private |
1.915 shares placement of common stock |
$19.2 |
Valentis sold 1.915M shares of common stock for $10 each to raise $19.2M; investors included the State of Wisconsin Investment Board, BayStar Capital and Merlin BioMed Asset Management in the U.S.; Framlington Asset Management, Park Place Capital and the Finsbury Trust in the UK; Compania Financiera Internacional and BSI-AG in Switzerland; and Banca Intermobiliare di Invetimenti in Italy (4/14) |
Notes: |
||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. |
||||
* Non-U.S. currencies converted at the exchange rate on the date of the announcement. |
||||
@ Dates listed are the dates of press releases, and are not necessarily the dates on which stated events took place. |
||||
ASX = Australian Stock Exchange; LSE = London Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange; OTC BB = Over The Counter Bulletin Board |